Co-Diagnostics (CODX) Tops Q2 EPS by $1.54, Beats on Revenue
Tweet
Share
E-mailGet Alerts CODX Hot Sheet
Join SI Premium – FREE
Co-Diagnostics (NASDAQ: CODX) reported Q2 EPS of ($1.46), $1.54 better than the analyst estimate of ($3.00). Revenue for the quarter came in at $170 thousand versus the consensus estimate of $132.58 thousand.
For earnings history and earnings-related data on Co-Diagnostics (CODX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
- Needham Reiterates Buy Rating on Digimarc (DMRC)
- Instil Bio Inc. (TIL) Misses Q2 EPS by 21c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
